Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Aug 08, 2022 3:17pm
237 Views
Post# 34879623

RE:If TH1902 does not work, we are done..YES or NO?

RE:If TH1902 does not work, we are done..YES or NO?It seems fair to assume it will be ugly if the TH-1902 trial flops. But what if it doesn't completely flop and there is some way forward? I suspect that is the more likely scenario of the ugly scenarios. At that point, it may be just a matter of how long it is expected to take to get to the new milestone that may, along with how crushed share price gets, that determines if it is worth stocking around. 

On partnerships, I don't think you see that from Western companies until they can announce compelling data. With regard to a Chinese partnership, I am not sure we can fully believe what the company has been saying for quite some time now about that. The Chinese drug companies, or at least the ones TH would like to partner with, may also be waiting for compelling actual data too.

If I knew if the delay in doing a Chinese partnership in cancer was truly tied to TH trying to high grade their partner, I would feel better about that situation. If we have not heard about a Chinese partnership soon, then one has to believe that is not happening until the data is so compelling there is no stopping such a partnership. 

TH1902 wrote: What do you all think? 

Patiently here for years and feel like I've been strung along with promise after promise from this company.

I think if the Oncology program flops, its over...thoughts and opinions?

I would maybe prefer a partnership sooner than later to offset risk going forward...biotechs are hard...


<< Previous
Bullboard Posts
Next >>